Glad to see a bit of push back against remuneration. Another small Aussie bio-tech with great products but overpaid executive and sales staff. Of course a lot of expenditure for coming pipeline products and sales, but the revenues beyond R&D rebates are far too slow. Too many Aussie bio-techs seem to have great products and overpaid staff with poor revenue growth, even allowing for COVID. They need a real turn around in the next six months to get to cash positive at the end of 2022 from a outsider's perspective. If they really do deliver on that then this company greatly undervalued, but I am a late to the party investor and having a bit of a punt at these low levels on yet another company that has FDA approved products, and it seems the company has failed to commercialise approvals quick enough for lponger-term investors' patience.
Add to My Watchlist
What is My Watchlist?
